Latest Independent Research Report on Nutriband Inc.

AVERSA Fentanyl Is Moving Forward. Nutriband reported results from 2Q26, ended July 31, 2025, with a loss of $2.12 per share. Revenues for 2Q26 were $0.6 million compared with $0.4 million in 2Q25. The increase was attributed to the expansion of contract manufacturing services in the Pocono Pharma division that produces kinesiology tape. Net loss was $2.0 million before Preferred Dividends of $21.8 million, bringing Net Loss Available To Shareholders to $23.8 million. Cash at the end of the quarter was $6.9 million.
 

Meeting With The FDA Later In September. The company has scheduled a meeting with the FDA on September 18, 2025, to discuss the upcoming Phase 1 clinical trial for AVERSA Fentanyl. This is a Type C Meeting, requested by the company to discuss product development. The meeting agenda includes the CMC (Chemistry, Manufacturing, and Controls) and other aspects of the Investigational New Drug Application (IND) using the 505(b)(2) route of regulatory approval.

 

Only One Phase 1 Trial Is Required. AVERSA Fentanyl is a patch that contains an approved drug with the company’s proprietary abuse-deterrent technology. The application for approval only requires one Phase 1 trial to test abuse potential, with an endpoint showing that the AVERSA Fentanyl patch is less preferable to abusers than the generic patch. No Phase 2 or Phase 3 trials are required. We expect the trial to begin late in CY2025.

​

Additional Product Expected After AVERSA Fentanyl. Following the completion of AVERSA Fentanyl development, we expect additional applications of the AVERSA abuse-deterrent technology to continue development. Buprenorphine is an opioid that can relieve opioid withdrawal symptoms and can block the effects of other opioids. It is one of the drugs used to treat opioid dependence. We believe that an AVERSA Buprenorphine patch would make administration more practical, easier, and increase the use of buprenorphine.